These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11093600)

  • 1. CPH 82 (Reumacon) in refractory inflammatory arthritis.
    Gudmundsdóttir ES; Jónsson H
    Scand J Rheumatol; 2000; 29(5):323-5. PubMed ID: 11093600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CPH-82 (Reumacon) versus auranofin (Ridaura): a 36-week study of their respective onset of action rates in RA.
    Bjørneboe O; Moen F; Nygaard H; Haavik TK; Svensson B
    Scand J Rheumatol; 1998; 27(1):26-31. PubMed ID: 9506874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical study of CPH 82 vs methotrexate in early rheumatoid arthritis.
    Lerndal T; Svensson B
    Rheumatology (Oxford); 2000 Mar; 39(3):316-20. PubMed ID: 10788542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CPH 82.
    BioDrugs; 2003; 17(5):373-4. PubMed ID: 14498767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difference in pharmacological activity between CPH 82 and podophyllotoxin.
    Rosén B
    Scand J Rheumatol; 1998; 27(2):159. PubMed ID: 9572647
    [No Abstract]   [Full Text] [Related]  

  • 6. Glucocorticoid-like anti-inflammatory versus immunosuppressive effects of CPH 82 as a single drug therapy of moderately active rheumatoid arthritis patients.
    Masi AT; Chatterton RT
    Scand J Rheumatol; 2000; 29(2):85-8. PubMed ID: 10777120
    [No Abstract]   [Full Text] [Related]  

  • 7. Endocrine effects of the podophyllotoxine derivative drug CPH 82 (Reumacon) in patients with rheumatoid arthritis.
    Carlström K; Hedin PJ; Jönsson L; Lerndal T; Lien J; Weitoft T; Axelson M
    Scand J Rheumatol; 2000; 29(2):89-94. PubMed ID: 10777121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CPH82 in rheumatoid arthritis. Accumulation of bone marrow cells in mitosis and clinical response.
    Rantapää-Dahlqvist S; Löfvenbert E; Norberg B
    Clin Rheumatol; 1993 Dec; 12(4):541-2. PubMed ID: 8124923
    [No Abstract]   [Full Text] [Related]  

  • 9. Reumacon (CPH82) showed similar x-ray progression and clinical effects as methotrexate in a two year comparative study on patients with early rheumatoid arthritis.
    Svensson B; Pettersson H
    Scand J Rheumatol; 2003; 32(2):83-8. PubMed ID: 12737326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis.
    Suissa S; Ernst P; Hudson M; Bitton A; Kezouh A
    Am J Med; 2004 Jul; 117(2):87-92. PubMed ID: 15234643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs for rheumatoid arthritis.
    Treat Guidel Med Lett; 2009 May; 7(81):37-46; quiz 47-8. PubMed ID: 19390497
    [No Abstract]   [Full Text] [Related]  

  • 13. Drugs for rheumatoid arthritis.
    Treat Guidel Med Lett; 2005 Dec; 3(40):83-90. PubMed ID: 16299450
    [No Abstract]   [Full Text] [Related]  

  • 14. Drugs for rheumatoid arthritis.
    Treat Guidel Med Lett; 2003 Jan; 1(5):25-32. PubMed ID: 15529103
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
    J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis.
    Mroczkowski PJ; Weinblatt ME; Kremer JM
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S66-8. PubMed ID: 10589360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug therapy of rheumatoid arthritis].
    Arndt U; Rittmeister M; Möller B
    Orthopade; 2003 Dec; 32(12):1095-103. PubMed ID: 14655006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of rheumatoid arthritis].
    Bolten WW
    MMW Fortschr Med; 2008 Aug; 150(32-35):50-3; quiz 54. PubMed ID: 19006884
    [No Abstract]   [Full Text] [Related]  

  • 19. Disease-modifying drugs in rheumatoid arthritis.
    Rahman A; Ahmed S; Underwood M
    Practitioner; 2001 Dec; 245(1629):1018-25. PubMed ID: 11771221
    [No Abstract]   [Full Text] [Related]  

  • 20. Podophyllum derivatives (CPH 82) compared with placebo in the treatment of rheumatoid arthritis.
    Larsen A; Petersson I; Svensson B
    Br J Rheumatol; 1989 Apr; 28(2):124-7. PubMed ID: 2706415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.